A new anti-aging therapeutic in the clinical pipeline could stand to disrupt multibillion-dollar legacy franchises like AbbVie’s Humira and Amgen’s Enbrel.
This new type of therapeutic, called senolytics, is being developed by four biotech companies right now, and analysts think the first market-ready product could become available as early as 2023.
Senolytics will be able to target all age-related diseases, eliminating the need for current therapeutics that are more limited in the range of diseases they can address.
A new therapeutic treatment might be making its way to the anti-aging market, and it could stand to disrupt multibillion-dollar franchises like AbbVie’s Humira and Amgen’s Enbrel.
According to a report from analysts at Citi GPS, many biotech companies are investing in developing senolytics, a new type of treatment to combat all aging-related disease.
These drugmakers include Unity Biotechnology, Oisin Biotechnologies, Siwa Therapeutics, and Google venture Calico. The first commercially available treatment could be here by 2023, according to the Citi report, but a proof of concept could be available as early as next year.
August 22, 2018